PAHC Stock Analysis: Buy, Sell, or Hold?
PAHC - Phibro Animal Health Corporation Class A
$55.52
0.76 (1.39%)
▲
5d:
-0.54%
30d:
+7.0%
90d:
+48.61%
BUY
MODERATE Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 06, 2026
Smart Money Accumulation
PAHC is down 3.9% this week, but smart money is accumulating calls. Top strike: $55 2026-05-15 with 11 OI. Call ratio: 85% View Scanner →
Strength: 5.4/10
Get Alerted When PAHC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: PAHC shows positive signals but monitor for confirmation. Market pricing in 2.5% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: PAHC shows positive signals but monitor for confirmation. Market pricing in 2.5% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$74.13
Based on 7.6% avg growth
INTRINSIC VALUE TODAY
$46.03
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 15.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PAHC is currently trading at $55.52, which is considered extended relative to its 30-day fair value range of $50.16 to $54.90. The stock's valuation (Forward PE: 16.5) is in line with its historical norms (15.3). At these levels, the market is pricing in 2.5% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, PAHC is in a strong uptrend. Immediate support is located at $49.89, while resistance sits at $57.62.
Market Sentiment: PAHC has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (26th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. However, the stock is trading significantly above the average Wall Street target of $48.50. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PAHC is in a strong uptrend. Immediate support is located at $49.89, while resistance sits at $57.62.
Market Sentiment: PAHC has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (26th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. However, the stock is trading significantly above the average Wall Street target of $48.50. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$50.16 -
$54.90
Company Quality Score
63/100
(BUY)
Options IV Signal
26th percentile
(COMPLACENCY WARNING)
Volume Confirmation
HIGH
Confidence Score
62.3%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 26th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BEARISH: Trading 12.6% above Wall St target ($48.50)
- NEUTRAL: Market pricing in 2.5% annual earnings growth - fairly valued
Fair Price Analysis
30-Day Fair Range
$50.16 -
$54.90
Current vs Fair Value
EXTENDED
Expected Move (7 Days)
±$4.93
(8.9%)
Support & Resistance Levels
Support Level
$49.89
Resistance Level
$57.62
Current Trend
Strong Uptrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
16.51
Wall Street Target
$48.50
(-12.6%)
Revenue Growth (YoY)
20.9%
Earnings Growth (YoY)
752.0%
Profit Margin
6.3%
Valuation Premium vs History
+2.5% premium
PE vs Historical
16.5 vs 15.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.5%
(market-implied from PE analysis)
1-Year Target
$56.91
(+3%)
2-Year Target
$58.33
(+5%)
3-Year Target
$59.79
(+8%)
3-Yr Target (if PE normalizes)
(PE: 17→15)
PE COMPRESSION
$55.42
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.6, Growth: 11.2%)
$95.25
(+72%)
Base:
(SPY PE: 16.5, Growth: 11.2%)
$76.43
(+38%)
Bear:
(PE: 14.0, Growth: 11.2%)
$64.96
(+17%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (22x PE), but valuation improves significantly next year (17x PE) as earnings recover.
Trailing PE: 22.46 | Current EPS (TTM): $2.26
Bull Case
$83.11
(+55%)
Analyst growth 48.8%, PE expands to 24.7
Base Case
$75.55
(+40%)
Market implied 48.8%, PE stable at 22.5
Bear Case
$34.52
(-36%)
Severe decline -20.0%, PE contracts to 19.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: April 02, 2026 5:10 PM ET
Data refreshes hourly during market hours. Next update: 6:10 PM
Data refreshes hourly during market hours. Next update: 6:10 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PAHC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
20
Sells
Net
INSIDERS SELLING
Recent Transactions
Jack Bendheim
SELL
5280 shares
2026-03-13
Jack Bendheim
SELL
7040 shares
2026-02-26
Jack Bendheim
SELL
7040 shares
2026-02-24
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$178 | 63 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$151 | 63 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$91 | 61 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 55 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$21 | 56 HOLD |
Advanced PAHC Option Strategies
Professional options setups generated by AI based on today's PAHC price and gamma walls.
